본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation

이용수 2

영문명
Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation
발행기관
대한방사선종양학회
저자명
Debnarayan Dutta Meenu Jose Sruthi Kalavagunta Ajay Sasidharan Haridas Nair Annex H. Edappattu
간행물 정보
『대한방사선종양학회지』제42권 제1호, 32~42쪽, 전체 11쪽
주제분류
의약학 > 종양학
파일형태
PDF
발행일자
2024.03.30
4,120

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Purpose: Retrospective audit of recurrent glioma patients treated by different fractionation schedules and to validate the modified Combs prognostic score in Indian patient cohort. Materials and Methods: Between Jan 2009 and June 2022, 66 recurrent gliomas patients treated with standard adjuvant treatment—radiation (RT) ± temozolomide (chemotherapy)—and re-treated with RT (± chemotherapy) were categorized as per modified Combs prognostic criteria and outcomes were compared. Results: Sixty-six patients with recurrent gliomas who received reirradiation (re-RT) were audited—53% males; 61% Karnofsky performance status (KPS) ≥80 at time of re-RT; median age 41.5 years (range, 6 to 70 years); 67% <50 years; primary histology low-grade glioma in 33% ; grade III 27%, grade IV 40%; initial median dose of 60 Gy equivalent dose in 2 Gy fractions (EQD2); maximum safe resection at recurrence 41%; mean and median follow-up 78 ± 51 months and 66 months. Mean time interval between RT was 46.4 ± 39 months. Mean planning target volume (PTV) volume in conventional RT (Conv-RT), hypofractionated RT (Hypo-RT), and ultra-hypofractionated RT (UF-RT) was 226.1 ± 140.7 mL, 162.8 ± 123.3 mL, and 143.3 ± 145.8 mL. Mean dose for Conv-RT, Hypo-RT, and UF-RT was 50 Gy (range, 40 to 60), 31 Gy (range, 20 to 40), and 20 Gy (range, 10 to 30). Mean overall survival (OS) in Conv-RT, Hypo-RT, and UF-RT cohort was 18.8 months (range, 2.4 to 76.8); 6.6 months (range, 2 to 17.4), and 13.9 months (range, 3 to 131.9). Median OS as per Combs criteria were 16.6 months (Group a), 24.6 months (Group b), 4.6 months (Group c), and 3 months (Group d). Significant survival benefit was with good KPS score (KPS >80 vs. <80; 20.46 vs. 5.25 months; p < 0.001), patients receiving salvage chemotherapy (20.46 vs. 6.96 months; p = 0.001), and patients received re-RT biological equivalent dose (BED3) >80 Gy (16.62 vs. 5.48 months; p = 0.03). Median overall survival (OS) in our patient cohort and Combs cohort in Group a was 16.6 and 19.5 months; Group b was 24.6 and 11.3 months; Group c was 4.7 and 8.1 months, and Group d was 2 and 5.5 months, respectively. Six months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 100%, 92%, 34%, 17% and 94%, 79%, 70%, 41%, respectively. Twelve months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 88%, 74%, 22%, 0% and 88%, 47%, 22%, 7%, respectively. Conclusion: Modified Combs prognostic factors predicts OS and is applicable in Indian subcontinent patient population.

목차

Introduction
Materials and Methods
Results
Discussion and Conclusion
Statement of Ethics
Conflict of Interest
Funding
Author Contributions
Data Availability Statement
References

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

Debnarayan Dutta,Meenu Jose,Sruthi Kalavagunta,Ajay Sasidharan,Haridas Nair,Annex H. Edappattu. (2024).Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation. 대한방사선종양학회지, 42 (1), 32-42

MLA

Debnarayan Dutta,Meenu Jose,Sruthi Kalavagunta,Ajay Sasidharan,Haridas Nair,Annex H. Edappattu. "Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation." 대한방사선종양학회지, 42.1(2024): 32-42

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제